Lipigon Pharmaceuticals
Umeå
About Lipigon Pharmaceuticals
Lipigon Pharmaceuticals is specialized in fat metabolism and develops new blood lipids. Lipigon is currently focusing on developing drugs directed against the enzyme lipoprotein lipase (LPL). People with low activity at LPL have a higher incidence of elevated blood fats and also related disorders such as insulin resistance and metabolic syndrome. Thanks to Lipigon's expertise in this area, AstraZeneca has chosen to enter into a cooperation agreement with the Company to develop LPL-based pharmaceuticals. Lipigon can receive up to $ 110 million in compensation at achieved milestones related to development and sales.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $10K – $50K
- Total funding: $852.5K
- Funding stage: IPO
- Last round: Seed (Feb 2019)
- Ticker: sto:LPGO
- Website: lipigon.se
- Phone: +46(0)705781768
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lipigon-pharmaceuticals-212183 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.